Thomas B. Hansen

Soborg, Denmark

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 9 publications

Superior weight loss with once-weekly semaglutide versus other glucagon-like peptide-1 receptor agonists is independent of gastrointestinal adverse events.

Superior weight loss with once-weekly semaglutide versus other glucagon-like peptide-1 receptor agonists is independent of gastrointestinal adverse events.

Journal: BMJ open diabetes research & care

Published: June 19, 2020

Effects of once-weekly subcutaneous semaglutide on kidney function and safety in patients with type 2 diabetes: a post-hoc analysis of the SUSTAIN 1-7 randomised controlled trials.

Effects of once-weekly subcutaneous semaglutide on kidney function and safety in patients with type 2 diabetes: a post-hoc analysis of the SUSTAIN 1-7 randomised controlled trials.

Journal: The lancet. Diabetes & endocrinology

Published: April 24, 2020

Cardiovascular risk reduction with once-weekly semaglutide in subjects with type 2 diabetes: a post hoc analysis of gender, age, and baseline CV risk profile in the SUSTAIN 6 trial.

Cardiovascular risk reduction with once-weekly semaglutide in subjects with type 2 diabetes: a post hoc analysis of gender, age, and baseline CV risk profile in the SUSTAIN 6 trial.

Journal: Cardiovascular diabetology

Published: March 31, 2019

Improved treatment satisfaction in patients with type 2 diabetes treated with once-weekly semaglutide in the SUSTAIN trials.

Improved treatment satisfaction in patients with type 2 diabetes treated with once-weekly semaglutide in the SUSTAIN trials.

Journal: Diabetes, obesity & metabolism

Published: March 25, 2019

A 26-Week Randomized Controlled Trial of Semaglutide Once Daily Versus Liraglutide and Placebo in Patients With Type 2 Diabetes Suboptimally Controlled on Diet and Exercise With or Without Metformin.

A 26-Week Randomized Controlled Trial of Semaglutide Once Daily Versus Liraglutide and Placebo in Patients With Type 2 Diabetes Suboptimally Controlled on Diet and Exercise With or Without Metformin.

Journal: Diabetes care

Published: November 13, 2017

Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial.

Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial.

Journal: The lancet. Diabetes & endocrinology

Published: November 09, 2016

Prediction of reversible IgG1 aggregation occurring in a size exclusion chromatography column is enabled through a model based approach.

Prediction of reversible IgG1 aggregation occurring in a size exclusion chromatography column is enabled through a model based approach.

Journal: Biotechnology journal

Published: April 01, 2014

Prediction of IgG1 aggregation in solution.

Prediction of IgG1 aggregation in solution.

Journal: Biotechnology journal

Published: January 12, 2014

Model-based design and integration of a two-step biopharmaceutical production process.

Model-based design and integration of a two-step biopharmaceutical production process.

Journal: Bioprocess and biosystems engineering

Published: October 04, 2013

Showing 1-9 of 9

Last Updated: 09/26/2026